Fresenius SE & Co. KGaA
(FSNUF)
Überblick & Kennzahlen
| Preis | 54.35 |
|---|
| Gehandeltes Volumen | 165 |
|---|
| Tageshoch | 57.0 |
|---|
| Tagestief | 57.0 |
|---|
| Eröffnung | 57.0 |
|---|
| Vortagesschluss | 54.35 |
|---|
| Marktkapitalisierung | 30,611,943,424 |
|---|
| Dividendenrendite | 227.00% |
Unternehmensprofil
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Finanzdaten (Jährlich)
|
2025-12-31 00:00:00 |
2024-12-31 00:00:00 |
2023-12-31 00:00:00 |
2022-12-31 00:00:00 |
2021-12-31 00:00:00 |
| Tax Effect Of Unusual Items |
4.990160e+07 |
0.000000e+00 |
0.000000e+00 |
0.000000e+00 |
NaN |
| Tax Rate For Calcs |
2.660000e-01 |
3.151010e-01 |
1.500000e-01 |
2.350000e-01 |
NaN |
| Normalized EBITDA |
3.565400e+09 |
3.473000e+09 |
2.692000e+09 |
3.099000e+09 |
NaN |
| Total Unusual Items |
1.876000e+08 |
NaN |
NaN |
NaN |
NaN |
| Total Unusual Items Excluding Goodwill |
1.876000e+08 |
NaN |
NaN |
NaN |
NaN |
| Net Income From Continuing Operation Net Minority Interest |
1.536000e+09 |
1.327000e+09 |
1.394000e+09 |
4.770000e+08 |
NaN |
| Reconciled Depreciation |
1.120000e+09 |
1.239000e+09 |
1.400000e+09 |
1.157000e+09 |
NaN |
| Reconciled Cost Of Revenue |
1.718000e+10 |
1.631700e+10 |
1.609600e+10 |
1.612900e+10 |
NaN |
| EBITDA |
3.753000e+09 |
3.473000e+09 |
2.692000e+09 |
3.099000e+09 |
NaN |
| EBIT |
2.633000e+09 |
2.234000e+09 |
1.292000e+09 |
1.942000e+09 |
NaN |
| Net Interest Income |
-3.200000e+08 |
-4.290000e+08 |
-3.980000e+08 |
-2.150000e+08 |
NaN |
| Interest Expense |
4.450000e+08 |
5.520000e+08 |
5.190000e+08 |
3.450000e+08 |
NaN |
| Interest Income |
1.160000e+08 |
1.230000e+08 |
1.210000e+08 |
1.300000e+08 |
NaN |
| Normalized Income |
1.398302e+09 |
1.327000e+09 |
1.394000e+09 |
4.770000e+08 |
NaN |
| Net Income From Continuing And Discontinued Operation |
1.264000e+09 |
4.710000e+08 |
-5.940000e+08 |
1.372000e+09 |
NaN |
| Total Expenses |
2.069160e+10 |
1.988100e+10 |
1.988400e+10 |
1.972000e+10 |
NaN |
| Total Operating Income As Reported |
2.310000e+09 |
2.073000e+09 |
1.183000e+09 |
1.812000e+09 |
NaN |
| Diluted Average Shares |
5.632373e+08 |
5.632373e+08 |
5.632373e+08 |
5.612643e+08 |
NaN |
| Basic Average Shares |
5.632373e+08 |
5.632373e+08 |
5.632373e+08 |
5.612643e+08 |
NaN |
| Diluted EPS |
2.240000e+00 |
8.400000e-01 |
-1.050000e+00 |
2.440000e+00 |
NaN |
| Basic EPS |
2.240000e+00 |
8.400000e-01 |
-1.050000e+00 |
2.440000e+00 |
NaN |
| Diluted NI Availto Com Stockholders |
1.264000e+09 |
4.710000e+08 |
-5.940000e+08 |
1.372000e+09 |
NaN |
| Average Dilution Earnings |
NaN |
NaN |
NaN |
0.000000e+00 |
0.0 |
| Net Income Common Stockholders |
1.264000e+09 |
4.710000e+08 |
-5.940000e+08 |
1.372000e+09 |
NaN |
| Otherunder Preferred Stock Dividend |
0.000000e+00 |
0.000000e+00 |
0.000000e+00 |
0.000000e+00 |
NaN |
| Net Income |
1.264000e+09 |
4.710000e+08 |
-5.940000e+08 |
1.372000e+09 |
NaN |
| Minority Interests |
-7.000000e+07 |
1.750000e+08 |
1.106000e+09 |
-7.450000e+08 |
NaN |
| Net Income Including Noncontrolling Interests |
1.334000e+09 |
2.960000e+08 |
-1.700000e+09 |
2.117000e+09 |
NaN |
| Net Income Discontinuous Operations |
-2.720000e+08 |
-8.560000e+08 |
-1.988000e+09 |
8.950000e+08 |
NaN |
| Net Income Continuous Operations |
1.606000e+09 |
1.152000e+09 |
2.880000e+08 |
1.222000e+09 |
NaN |
| Tax Provision |
5.820000e+08 |
5.300000e+08 |
4.850000e+08 |
3.750000e+08 |
NaN |
| Pretax Income |
2.188000e+09 |
1.682000e+09 |
7.730000e+08 |
1.597000e+09 |
NaN |
| Special Income Charges |
1.876000e+08 |
NaN |
NaN |
NaN |
NaN |
| Other Special Charges |
-1.876000e+08 |
NaN |
NaN |
NaN |
NaN |
| Net Non Operating Interest Income Expense |
-3.200000e+08 |
-4.290000e+08 |
-3.980000e+08 |
-2.150000e+08 |
NaN |
| Total Other Finance Cost |
-9.000000e+06 |
NaN |
NaN |
NaN |
NaN |
| Interest Expense Non Operating |
4.450000e+08 |
5.520000e+08 |
5.190000e+08 |
3.450000e+08 |
NaN |
| Interest Income Non Operating |
1.160000e+08 |
1.230000e+08 |
1.210000e+08 |
1.300000e+08 |
NaN |
| Operating Income |
2.181400e+09 |
2.073000e+09 |
1.183000e+09 |
1.812000e+09 |
NaN |
| Operating Expense |
3.511600e+09 |
3.564000e+09 |
3.788000e+09 |
3.591000e+09 |
NaN |
| Other Operating Expenses |
2.190000e+08 |
3.250000e+08 |
5.170000e+08 |
2.110000e+08 |
NaN |
| Research And Development |
6.330000e+08 |
6.410000e+08 |
6.610000e+08 |
6.390000e+08 |
NaN |
| Selling General And Administration |
2.883000e+09 |
2.888000e+09 |
3.027000e+09 |
3.094000e+09 |
NaN |
| Selling And Marketing Expense |
6.150000e+08 |
6.790000e+08 |
7.420000e+08 |
7.460000e+08 |
NaN |
| General And Administrative Expense |
2.268000e+09 |
2.209000e+09 |
2.285000e+09 |
2.348000e+09 |
NaN |
| Gross Profit |
5.693000e+09 |
5.637000e+09 |
4.971000e+09 |
5.403000e+09 |
NaN |
| Cost Of Revenue |
1.718000e+10 |
1.631700e+10 |
1.609600e+10 |
1.612900e+10 |
NaN |
| Total Revenue |
2.287300e+10 |
2.195400e+10 |
2.106700e+10 |
2.153200e+10 |
NaN |
| Operating Revenue |
2.287300e+10 |
2.195400e+10 |
2.106700e+10 |
2.153200e+10 |
NaN |
Haupteigner
| Breakdown |
Value |
| insidersPercentHeld |
0.27008 |
| institutionsPercentHeld |
0.45684 |
| institutionsFloatPercentHeld |
0.62588 |
| institutionsCount |
563.00000 |
Letzte Analystenempfehlungen
Keine Empfehlungen verfügbar.